Alto Neuroscience (ANRO) Interest & Investment Income (2023 - 2026)
Alto Neuroscience (ANRO) posted Interest & Investment Income of $1.6 million for Q1 2026, little changed sequentially from $1.6 million in Q4 2025, and down 14.56% YoY from $1.8 million in Q1 2025.
Analysis
Alto Neuroscience (ANRO) Interest & Investment Income (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Interest & Investment Income for 4 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Interest & Investment Income fell 14.56% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 30.52% YoY) and the FY2025 annual result came in at $6.6 million, down 25.4% from the prior year.
- Interest & Investment Income was little changed at $1.6 million in Q1 2026 per ANRO's latest filing, from $1.6 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $2.7 million in Q2 2024 and troughed at $230000.0 in Q1 2023.
- A 4-year average of $1.5 million and a median of $1.6 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income soared 577.39% in 2024, then sank 38.72% in 2025.
- Over 4 years, Interest & Investment Income stood at $738000.0 in 2023, then surged by 189.3% to $2.1 million in 2024, then slipped by 26.89% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $1.6 million, $1.6 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | 2.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.11 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 2.14 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.66 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Dec 31, 2023 | 738,000.00 |
| Sep 30, 2023 | 714,000.00 |
| Jun 30, 2023 | 667,000.00 |
| Mar 31, 2023 | 230,000.00 |